Patent Application
20190321318
Droxidopa is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline) and which is used to increase the concentrations of these neurotransmitters in the body and brain. Chemically, droxidopa is (−)-threo-3-(3,4-Dihydroxyphenyl)-L-serine, and has the following structural formula:
Unlike norepinephrine and epinephrine themselves, droxidopa is capable of crossing the protective blood-brain barrier (BBB). It is metabolized by aromatic L-amino acid decarboxylase (AAAD), also known as DOPA decarboxylase (DDC).
Droxidopa is used to treat neurogenic orthostatic hypotension. Neurogenic orthostatic hypotension has a variety of causes and is also a common symptom of Parkinson's disease. Droxidopa is thought to work by increasing the levels of norepinephrine and epinephrine in the peripheral nervous system (PNS), which induces tachycardia or increased heart rate and hypertension or increased blood pressure, thus enabling the body to maintain blood flow upon and while standing.
The droxidopa dosage form currently approved for use in the United States is immediate release oral capsules comprising 100, 200, or 300 mg droxidopa, with a maximum daily dosage limited to 1800 mg. Current dosing regimens are administration of one or two capsules three times daily.
Disclosed, in various embodiments, are oral dosage forms comprising droxidopa, or a pharmaceutically acceptable salt thereof.
In some aspects, the disclosure is directed to a pharmaceutical composition comprising droxidopa, or a pharmaceutically acceptable salt thereof, for oral administration, wherein the pharmaceutical composition is an extended release liquid dosage form or solid dosage form. In some embodiments, the liquid dosage form is a solution, a suspension or an emulsion. In some embodiments, the solid dosage form comprises a solid composition packaged in a bottle, a sachet, or a packet for suspension in a liquid vehicle.
Certain aspects of the disclosure are directed to an extended-release liquid composition for oral administration comprising: (a) a multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a release controlling agent; and (b) a liquid vehicle.
In some embodiments, the extended-release liquid composition comprises: (a) an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a release-controlling agent; and (b) a liquid vehicle. In some embodiment, the release controlling agent is a non-polymeric material. In some embodiments, the extended-release multi-particulate further comprises a coating. In some embodiments, the multi-particulate is in the form of pellets, granulates, or a mini-tablets. In some embodiments, the multi-particulate comprises two or more types of pellets, e.g., one type can be immediate release pellets whereas another type can release the drug over an extended period. In some embodiments, the multi-particulate comprises two types of extended release pellets with each type having a different release profile. In some embodiments, at least one type of the pellets is coated. In some embodiments, all types of of the pellets are coated.
In some embodiments, the liquid vehicle has a pH of less than 7.0. In some embodiments, the liquid vehicle includes a buffering agent.
In an embodiment, an extended-release suspension or suspension for oral administration includes an extended-release multi-particulate including an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a release-controlling agent; and a suspending vehicle, wherein the suspension has a pH<7.0.
In some aspects, the disclosure is directed to a solid composition comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a release controlling agent, wherein the solid composition is an extended-release multi-particulate. In an embodiment, a solid pharmaceutical composition for oral administration includes an extended-release multi-particulate including an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a non-polymeric release-controlling agent. In some embodiments, the solid pharmaceutical composition suitable for suspension in a liquid vehicle.
In an embodiment, a pharmaceutical kit includes a solid pharmaceutical composition disclosed herein and a liquid vehicle. In some embodiments, the pharmaceutical kit comprises a solid pharmaceutical composition disclosed herein in a container such as a sachet or a bottle. In some embodiments, the disclosure is directed to a pharmaceutical kit comprising: (a) a solid composition comprising: (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and optionally, a first release controlling agent and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a second release controlling agent; and (b) a liquid vehicle. In some embodiments, the pharmaceutical kit comprises (a) an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a release-controlling agent; and (b) an immediate-release composition (e.g., a capsule) comprising an effective amount of droxidopa.
Methods of making the dosage form and methods of treating a subject with the dosage form are also disclosed.
In some aspects, a composition or dosage form of the disclosure is used for treating a subject in need of treatment of hypotension, neurogenic orthostatic hypotension (nOH), intradialytic hypotension, a symptom of Parkinson's disease, orthostatic hypotension associated with Parkinson's disease, postural instability associated with Parkinson's disease, postural orthostatic tachycardia syndrome (POTS), Down's syndrome, a demyelinating disease, Alzheimer's disease, an attention deficit disorder, hypersomnia, pain associated with fibromyalgia, motor paralysis, motor aphasia, urinary incontinence, dementia, antidiuresis, postural tachycardia syndrome, tauopathy, fatigue, headaches, neurological deficits or neuronal death induced by brain ischemia, intracranial hypertension or cerebral edema, cancer, a bacterial infection, to induce or facilitate micturition, nasal congestion, acute pain, chronic pain, or any combination thereof.
These and other features and characteristics are more particularly described below.
The following is a brief description of the drawings which are presented for the purposes of illustrating the exemplary embodiments disclosed herein and not for the purposes of limiting the same.
Currently approved dosing regimens for droxidopa are administration of one or two capsules three times daily. Patients typically treated with droxidopa, for example Parkinson's patients, have difficulty with vertical stability and/or difficulty swallowing large capsules. Patients administered capsules can also feel uncomfortable because capsules can stick to their throat. Three times daily dosing is inconvenient and can decrease patient compliance. To address these problems, the inventors have developed alternative oral dosage forms that are easier and more comfortable to swallow, and/or whose release properties permit dosing fewer than three times daily. This application discloses extended release droxidopa dosage forms, e.g., a solid dosage form that can be reconstituted to a liquid dosage form or a ready-to-use liquid dosage form. In some embodiments, the pharmaceutical compositions disclosed herein allow for oral administration only once or twice daily.
Disclosed herein are improved oral dosage forms comprising droxidopa such as, for example, extended-release formulations, which are more easily administered than currently marketed dosage and require fewer dosage forms to be administered daily.
In one aspect, the extended release dosage form is a solid pharmaceutical composition. The composition comprises an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a non-polymeric release-controlling agent.
In another aspect, the extended release dosage form is a suspension for oral administration. The suspension can comprise an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a release-controlling agent; and a suspending vehicle, wherein the suspension has a pH<7.0.
In some embodiments, the suspension has a pH less than 5.0. In some embodiments, the suspension has a pH of from about 2.0 to about 5.0, or from about 3.0 to about 5.0. In some embodiments, the suspension has a pH of about 4.0.
In some embodiments, the compositions or oral dosage forms disclosed herein comprise a multi-particulate (used interchangeably herein with “multi-particulates”), e.g., an extended release multi-particulate. Multi-particulates are discrete, small drug units, exhibiting a desired characteristic, that make up a multiple unit drug delivery system. The multi-particulates can be in the form of, for example, a drug particle, a granule, a pellet, a bead, a sphere, or a mini-tablet. Any of these multi-particulate forms can be coated or uncoated. In some embodiments, a desired characteristic of the multi-particulates is particle size, e.g., less than about 400 μm. In another embodiment, a desired characteristic of the multi-particulates is controlled release (e.g., extended release) of the drug (e.g., droxidopa or a pharmaceutically acceptable salt thereof) over a period of time.
In some embodiments, the multi-particulate comprises droxidopa or a pharmaceutically acceptable salt thereof. In some embodiments, the multi-particulate comprises a release controlling agent. In some embodiments, the multi-particulate comprises a coating. In some embodiments, the multi-particulate comprises a wax/lipid matrix (e.g., the multi-particulate are wax/lipid embedded matrix pellets). In some embodiments, the droxidopa is about 10% to about 70% (e.g. about 15% to about 35%) of the total weight of the multi-particulate. In some embodiments, the droxidopa is about 20% of the total weight of the multi-particulate.
The extended release multi-particulate can further comprise an excipient, e.g., a lubricant, a binder, a filler, a glidant, a plasticizer, or a combination thereof. Examples of suitable lubricants include sodium stearyl fumarate, stearic acid, magnesium stearate, glyceryl behenate, talc, and combinations comprising one or more of the foregoing lubricants. Examples of suitable binders include water-soluble polymer, such as modified starch, gelatin, polyvinyl alcohol, and combinations comprising one or more of the foregoing binders. Another suitable binder includes hydroxyproply cellulose alone or in combination with another binder. Examples of suitable fillers include lactose, microcrystalline cellulose, and combinations comprising one or more the foregoing fillers. An example of a glidant is colloidal silicon dioxide (AEROSIL, Evonik). An example of a suitable plasticizer is triethyl citrate, propylene glycol, or polyethylene glycol.
In some embodiments, the extended release multi-particulates have a particle size (e.g., d50) of less than 500 μm, less than 450 μm, less than 400 μm, less than 350 μm, less than 300 μm, less than 250 μm, less than 200 μm, about 450 μm to about 1 μm, about 450 μm to about 10 μm, about 450 μm to about 20 μm, about 450 μm to about 50 μm, about 450 μm to about 100 μm, about 400 μm to about 1 μm, about 400 μm to about 10 μm, about 400 μm to about 20 μm, about 400 μm to about 50 μm, about 400 μm to about 100 μm, or any combination thereof.
In some embodiments, the extended-release multi-particulates can further comprise a pH-controlling agent. The amount of a pH-controlling agent is sufficient to provide pH independent release of droxidopa from the multi-particulate.
Examples of a pH controlling agent (term used interchangeably with a pH modifier or a buffering agent) include pharmaceutically acceptable buffering systems, acids having suitable pKa and/or their salts, for example citric acid, citrate salts, tartaric acid, tartarate salts, succinic acid, succinate salts, acetic acid, acetate salts, fumaric acid, and fumarate salts. Inorganic acids can also be used, including hydrochloric or sulfuric acid.
In some embodiments, the pH modifier is not in direct contact with droxidopa, or a pharmaceutically acceptable salt thereof of the multi-particulate. In some embodiments, the liquid vehicle comprises a pH modifier (e.g., monosodium citrate or sodium bitartarate) 0.1% w/v to 1.0% w/v of the liquid dosage (e.g., suspension) volume.
In some embodiments, a multi-particulate disclosed herein is combined with a liquid vehicle. In some embodiments, the liquid vehicle can comprises a pH modifier. In some embodiments, the pH modifier is chosen such that when supplied as ready-to-use suspension or when the multi-particulates are reconstituted or suspended with a liquid vehicle, such as water, the pH modifier can maintain the pH of the reconstituted liquid dosage form, e.g., at a pH of <7.0, for example, from about 6.0 to about 7.0, from about 2.0 to about 5.0, from about 2.0 to about 4.5, from about 2.0 to about 4.0, from about 2.5 to about 5.0, from about 2.5 to about 4.5, from about 2.5 to about 4.0, from about 3.0 to about 5.0, from about 3.5 to about 4.5, or from about 3.5 to about 4.0. In some embodiments, the liquid dosage form has a pH of about 4.0.
In other embodiments, the liquid dosage form comprising a multi-particulate has a pH above 7.0, such as about 7.0 to about 8.0, or about 7.0 to about 9.0. In some liquid dosage forms, droxidopa is protected from degradation by a protective layer that prevents exposure of the drug to the high pH.
In some embodiments, the multi-particulate does not comprise a pH-controlling agent.
The multi-particulate can also be coated with a protection layer. In some embodiments, the protection layer prevents drug release from the multi-particulates reconstituted or suspended into a liquid dosage form or into the food on which it is sprinkled. Examples of a protection layer include, for example, a moisture protection layer, a light protection layer, an integrity protection layer to prevent friable dosage forms from crumbling, a taste masking protective layer, and protective layers that increase ease of swallowing. Examples of materials that may be used in a moisture protection layer include a cationic methacrylate copolymer, for example EUDRAGIT E100, a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, methyl methacrylate, or a combination of the foregoing. Polyvinyl alcohol, ethyl cellulose, and hydroxypropyl methyl cellulose may also be used in moisture protection layers and other types of protection layers. Unless clearly indicated by the context of this disclosure, protection layers do not significantly affect drug release profiles and are not controlled release coatings.
In some embodiments, the extended-release multi-particulate can comprise or be combined with a release-controlling agent. The release-controlling agent can comprise a polymer, a non-polymeric material, or a combination thereof.
Examples of a polymeric release controlling agent include shellacs, ethylcellulose, cellulose acetate phthalate, acrylic resins, methacrylate hydrogels, methylmethacrylate, polymethacrylate, polylactic acid, polyvinyl acetate, polyvinyl chloride, polymethacrylate, hydroxypropylmethylcellulose, polyethylene glycols, carboxymethylcellulose, sodium carboxymethylcellulose, and combinations thereof.
The non-polymeric release-controlling agent can comprise a wax, a lipophilic compound, or a combination thereof.
The wax can be, for example, an amorphous wax, an anionic wax, an anionic emulsifying wax, a bleached wax, a carnauba wax, a cetyl esters wax, a beeswax, a castor wax, a cationic emulsifying wax, a cetrimide emulsifying wax, an emulsifying wax, a glyceryl behenate, a microcrystalline wax, a nonionic wax, a nonionic emulsifying wax, a paraffin, a petroleum wax, a spermaceti wax, a white wax, a yellow wax, and combinations comprising one or more of the foregoing waxes. These and other suitable waxes are known to those of skill in the art. A cetyl esters wax, for example, preferably has a molecular weight of about 470 to about 490 and is a mixture containing primarily esters of saturated fatty alcohols and saturated fatty acids. The wax can comprise a carnauba wax, glyceryl behenates (e.g., glyceryl dibehenate), castor wax, and combinations comprising one or more of the foregoing waxes.
The wax material can be used at about 10 wt % to about 70 wt %, 13 wt % to about 55 wt %, about 16 wt % to about 40 wt %, about 20 wt % to about 36 wt %, about 24 wt % to about 33 wt % of the total weight of the multi-particulate. When a combination of wax is used, e.g., carnauba wax and glyceryl behenate, the component waxes can be used in a suitable ratio. Certain formulations include the wax material component from 100 to about 85 parts carnauba wax and from 0 to about 15 parts glyceryl behenate. In formulations that have a combination of carnauba wax and castor wax, for example, the wax component may have about 100 to about 85 parts carnauba wax and 0 to about 15 parts castor wax. When carnauba wax, glyceryl behenate and castor wax are present, the carnauba wax can comprise at least about 85 wt % of the waxy material and the balance of the waxy material is made up of a combination of glyceryl behenate and castor wax, in a suitable relative proportion.
The lipophilic compound can be, for example, a fatty acid, a fatty acid soap; a fully or partially hydrogenated vegetable oil or fat; or a mono-, di-, or triacylglceride. The fatty acids and fatty acid soaps can be those that are generally used in the pharmaceutical industry as tableting lubricants, such as, for example, solid fatty acids (for example fatty acids having from about 16 to about 22 carbon atoms), and the alkaline earth metal salts thereof, particularly the magnesium and calcium salts, and combinations comprising one or more of the foregoing fatty acids. The fatty acid can be, for example, stearic acid. Examples of the fully or partially hydrogenated vegetable oil or fat include hydrogenated palm fat and oil, hydrogenated castor oil, hydrogenated rape oil, hydrogenated cottonseed oil, hydrogenated soybean oil, and hardened soybean oil. Examples of a mono-, di-, or triglyceride include glyceryl monolaurate; glyceryl dilaurate; glyceryl monomyristate; glyceryl dimyristate; glyceryl monopalmitate; glyceryl dipalmitate; glyceryl monostearate; glyceryl distearate; glyceryl monooleate; glyceryl dioleate; glyceryl monolinoleate; glyceryl dilinoleate; glyceryl monoarachidate; glyceryl diarachidate; and glyceryl dibehenate, glycerol behenate, glyceryl palmitostearate, trilaurin, trimyristan, tripalmitin, tristearin, and tribehenin. The lipophilic compound can be used in amounts of up to about 70 wt % of the total weight of the multi-particulate, or about 2.5 wt % to about 55 wt %, or about 2.7 wt % to about 40 wt %, or from about 3 wt % to about 36 wt %, or from about 3.5 wt % to about 33 wt % of the total weight of the multi-particulate.
In some embodiments, the oral dosage form disclosed herein comprises immediate release multi-particulates and extended release multi-particulates. In some embodiments, the oral dosage form disclosed herein comprises fast release multi-particulates and extended release multi-particulates. In certain embodiments, the oral dosage form comprises two or more types of extended-release multi-particulates comprising droxidopa, or a pharmaceutically acceptable salt thereof. Each type of extended-release multi-particulate can have a different extended release profile for droxidopa, or the pharmaceutically acceptable salt thereof.
In certain embodiments, the droxidopa, or the pharmaceutically acceptable salt thereof, is released from a first multi-particulate at a pH of about 1.0 to about 3.5 (e.g., about pH 1.2) and the droxidopa, or the pharmaceutically acceptable salt thereof, is released from a second multi-particulate at a pH of about 4.0 to about 6.0 (e.g., about pH 5.5). In some embodiments, the first multi-particulate and the second multi-particulate are pellets, granulates, or mini-tablets. In a further embodiment, the composition can comprise an immediate release multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof.
In some embodiments, the composition or suspension disclosed herein comprises (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and optionally a first release controlling agent; and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a second release controlling agent. In some embodiments, the release controlling agent (e.g., the first and/or second release controlling agent) is non-polymeric release controlling agent. In some embodiments, the release controlling agent (e.g., the first and/or second release controlling agent) comprises a wax or a wax/lipid matrix. In some embodiments, the composition or suspension further comprises a liquid vehicle.
In some embodiments, the composition or suspension disclosed herein comprises (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, in an immediate release form, and a moisture protective layer (e.g., EUDRAGIT E100); and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a release controlling agent. In one embodiment, the second multi-particulate comprises a wax/lipid matrix (e.g., hydrogenated castor oil). In one embodiment, the second multi-particulate is coated with a protective layer (e.g., EUDRAGIT 30-D55). In one embodiment, the second multi-particulate is coated with a moisture protective layer (e.g., EUDRAGIT E100).
In some embodiments, the composition or suspension disclosed herein comprises (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, in fast release form, and a moisture protective layer (e.g., EUDRAGIT E100); and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a release controlling agent. In one embodiment, the second multi-particulate comprises a wax/lipid matrix (e.g., hydrogenated castor oil). In one embodiment, the second multi-particulate is coated with a protective layer (e.g., EUDRAGIT 30-D55). In one embedment, the second multi-particulate is coated with a moisture protective layer (e.g., EUDRAGIT E100).
In some embodiments, the composition or suspension disclosed herein comprises (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a first release controlling agent; and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a second release controlling agent. In one embodiment, the first multi-particulate comprises a wax or a wax/lipid matrix (e.g., glyceryl dibehenate). In one embodiment, the first multi-particulate does not comprise a protective layer. In one embodiment, the second multi-particulate comprises a wax or a wax/lipid matrix (e.g., hydrogenated castor oil). In one embedment, the second multi-particulate is coated with a protective layer (e.g., EUDRAGIT 30-D55). In one embedment, the second multi-particulate does not comprise a moisture protective layer.
In some embodiments, the composition or suspension disclosed herein comprises (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a first non-polymeric release controlling agent (e.g., a wax); and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a second non-polymeric release controlling agent (e.g., a wax). In some embodiments, the composition or suspension further comprises an aqueous liquid vehicle comprising a pH modifier (e.g., monosodium citrate and/or sodium bitartarate) and a suspending agent (e.g., xantham gum). In some embodiments, the first multi-particulate comprises 200 mg to 400 mg (e.g., about 300 mg) of droxidopa and the second multi-particulate comprises 500 mg to 700 mg (e.g., about 600 mg) of droxidopa. In some embodiments, the wax is glyceryl dibehenate. In some embodiments, the second multi-particulate is coated with a protective layer (e.g. EUDRAGIT 30-D55). In some embodiments, the liquid vehicle further comprises a preservative, a filler, a sweetener, a flavoring agent, a coloring agent, a pH modifier, or any combination thereof. In some embodiments, the aqueous liquid vehicle has a pH of less than 7, e.g., about 3 to 5, preferably about 4.
In some embodiments, the first and/or second multi-particulate can comprise a pH controlling agent, such as a citrate, a tartrate, or combinations thereof (e.g., sodium bitartarate, monosodium citrate).
In some embodiments, the multi-particulate are pellets. In some embodiments, the pellets are formed by direct pelletization. In some embodiments, the pellets have a particle size of less than 400 μm.
In some embodiments, the multi-particulate is a pulsatile release multi-particulate. The composition or suspension disclosed herein can comprises one or more types of pulsetile release multi-particulates comprising droxidopa, or a pharmaceutically acceptable salt thereof. Each type of pulsetile release multi-particulates releases the drug at a different time. In one embodiment, the composition or suspension comprises two types of pulsetile release multi-particulates. In another embodiment, the composition or suspension comprises three types of pulsetile release multi-particulates.
Pulsatile release multi-particulates for each pulse can release the same or different amounts of the active agent. In some embodiments, pulsatile release multi-particulates for each pulse releases the same amount of the active agent. In some embodiments, pulsatile release multi-particulates for each pulse releases a different amount of the active agent.
Pulsatile release multi-particulates for each pulse can have the same or different extended release periods. In some embodiments, pulsatile release multi-particulates for each pulse have the same extended release period, such as about 4 hours. In some embodiments, pulsatile release multi-particulates for each pulse have the same or a different extended release period, e.g., an extended release period of about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, or any combination thereof.
A daily dosage amount of droxidopa, or a pharmaceutically acceptable salt thereof, in the oral dosage form is about 100 mg to about 1800 mg or about 100 mg to about 3000 mg. In some embodiments, the composition comprising droxidopa, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 100 mg to about 3000 mg, about 200 mg to about 3000 mg, about 300 mg to about 3000 mg, about 400 mg to about 3000 mg, about 500 mg to about 3000 mg, about 600 mg to about 3000 mg, about 700 mg to about 3000 mg, about 800 mg to about 3000 mg, about 900 mg to about 3000 mg, about 1000 mg to about 3000 mg, about 1500 mg to about 3000 mg, about 2000 mg to about 3000 mg, about 100 mg to about 1800 mg, about 200 mg to about 1800 mg, about 300 mg to about 1800 mg, about 400 mg to about 1800 mg, about 500 mg to about 1800 mg, about 600 mg to about 1800 mg, about 700 mg to about 1800 mg, about 800 mg to about 1800 mg, about 900 mg to about 1800 mg, about 500 mg to about 1200 mg, about 600 mg to about 1000 mg, or about 800 mg to about 1000 mg once or twice daily. In some embodiments, the composition comprising droxidopa, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, about 2500 mg, about 2600 mg, about 2700 mg, about 2800 mg, about 2900 mg, or about 3000 mg once or twice daily.
In some embodiments, the composition or suspension disclosed herein provides for a daily dosage of about 330 mg to about 500 mg, about 660 mg to about 1000 mg, about 495 mg to about 1500 mg, about 990 mg to about 1500 mg, about 990 mg to about 3000 mg, or about 100 mg to about 3000 mg of droxidopa, or a pharmaceutically acceptable salt thereof.
In some embodiments, the composition or suspension disclosed herein provides for a one time daily dosage of about about 990 mg to about 3000 mg of droxidopa, or a pharmaceutically acceptable salt thereof. In some embodiments, the composition or suspension disclosed herein provides for a twice daily dosage of about about 495 mg to about 1500 mg of droxidopa, or a pharmaceutically acceptable salt thereof.
The extended release oral dosage form can provide a droxidopa plasma level in a subject of about 0.5 μg/mL to 5 μg/mL for a duration of about 4 to 24 hours or about 4 to 16 hours after oral administration of the composition to the subject.
The composition can be packaged to provide a single dose or multiple doses, for example 2, 3, 4, 5, 6, 7, 8, or more doses. The composition can be packaged to provide a single daily dosage amount or the daily dosage amount for multiple days, for example at least 3, 4, 5, 6, or 7 days.
In certain embodiments, the composition can be in the form of a capsule filled with the extended-release multi-particulate. In yet other embodiments, the composition is in the form of a compressed tablet comprising the multiparticulate. Alternatively, the composition can be in the form of a sealed package, such as a sachet, a two compartment sachet or the cap of a bottle, into which the multi-particulate has been filled. In another embodiment, the composition can be in the form of a suspension comprising one or more types of multi-particulates and a suspending vehicle.
In some embodiments, a solid pharmaceutical composition disclosed herein (e.g., a multi-particulate) is suitable for being reconstituted or suspended as a liquid dosage form (e.g., a solution, a suspension, or an emulsion) or to be sprinkled on food or in a drink.
Some aspects of the application are directed to an extended-release suspension for oral administration comprising (a) an extended-release multi-particulate of the application and a release-controlling agent; and (b) a liquid vehicle.
In another aspect, the application is directed to a solid composition comprising an extended-release multi-particulate of the application, which is suitable for reconstitution or suspension in a liquid vehicle. In some embodiments, the solid composition is packaged in a sachet, a bottle or a packet. In some embodiments, the solid composition is combined with a liquid vehicle, e.g., water, for oral administration.
The liquid vehicle can be an aqueous vehicle or a nonaqueous vehicle. Examples of aqueous vehicles include water and a buffered solution. Examples of nonaqueous vehicles include glycerin and propylene glycol.
The liquid vehicle can comprise excipients such as a stabilizer, a suspending agent, a flavoring agent, or a combination thereof. The liquid vehicle can be a suspending vehicle. In some embodiments, the suspending vehicle can comprise excipients such as suspending agent, a filler, a sweetener, a viscosity modifier, a flowing aid, a pH modifier, a preservative, a surfactant, a flavoring agent, a coloring agent, or a combination thereof.
In some embodiments, the liquid vehicle comprises a suspending agent. In some embodiments, the suspending agent is 0.1% w/v to 1.0% w/v of the liquid vehicle (e.g., suspension) volume. In some embodiments, the suspending agent is xanthan gum, guar gum, sodium carboxymethycellulose, hydroxypropyl cellulose, hypromellose, or any combination thereof.
In some embodiments, the liquid vehicle comprises a preservative. In some embodiments, the preservative is up to 100 mg per unit. In some embodiments, the preservative is 0.2% w/v to 1% w/v of the liquid vehicle (e.g., suspension) volume. In some embodiments, the preservative is sodium benzoate, potassium sorbate, sodium propionate, methylparaben, propylparaben, benzoic acid, sorbic acid, boric acid, or any combination thereof.
In some embodiments, the liquid vehicle, solution, suspension, or emulsion has a pH<7.0. In some embodiments, the pH is from 7.0 to 8.0, or from 7.0 to 9.0. In some embodiments, the pH is less than 5.0. In some embodiments, the pH is from about 2.0 to about 5.0, or from about 3.0 to about 5.0. In some embodiments, the pH is about 4.0.
In some embodiments, the liquid vehicle has a pH of less than 7.0. In some embodiments, the liquid vehicle includes pH modifier. In some embodiments, the liquid vehicle does not include a pH modifier.
Examples of a pH modifier include pharmaceutically acceptable buffering systems, acids having suitable pKa and/or their salts, for example citric acid, citrate salts, tartaric acid, tartarate salts, succinic acid, succinate salts, acetic acid, acetate salts, fumaric acid, and fumarate salts. Inorganic acids can also be used, including hydrochloric or sulfuric acid.
The liquid vehicle can further comprise a polymer that forms an in situ gel in the gastrointestinal tract. The liquid vehicle for reconstituting a solid droxidopa multi-particulate into a liquid dosage form may comprise materials which are in solution or suspension form before administration to the subject, but once administered undergo gelation in situ in the body to form a gel from which the drug is released in a sustained and controlled manner. The formation of a gel depends on various factors such as temperature modulation, pH change, and the presence of ions. Examples of polymers that can be used in the liquid vehicle for formation of an in situ gel after administration include gellan gum (induced by cations), sodium alginate (induced by cations), xyloglucan (induced by temperature), pectin (induced by calcium cation), chitosan, carbomer (induced by pH), poly(DL-lactic acid), poly(DL-lactide-co-glycolide), and poly-caprolactone.
In some embodiments, the volume of the liquid dosage form (e.g., a solution, a suspension, or an emulsion) to be administered to a subject is about 5 mL to about 100 mL (e.g., about 10 mL to about 100 mL, about 10 mL to about 75 mL, or about 30 mL to about 60 mL). In some embodiments, the liquid dosage form is administered once or twice daily. In some embodiments, a dose of about 100 mg to about 1800 mg or about 100 mg to about 3000 mg of droxidopa, or a pharmaceutically acceptable salt thereof, in a liquid dosage from is administered to a subject in need thereof.
In some embodiments, the liquid composition (e.g., a solution, a suspension, or an emulsion) comprising a multi-particulate comprising droxidopa, or pharmaceutically acceptable salt there, is stable when stored at room temperature or 4° C. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days after reconstitution or suspension of the droxidopa, or the pharmaceutically acceptable salt there, in a liquid vehicle. In some embodiments, the droxidopa, or the pharmaceutically acceptable salt there, present in the liquid vehicle or the suspending vehicle is stable at room temperature or 4° C. for at least 7 days, at least 10 days, at least 14 days, or at least 21 days (e.g., at least one week, at least two weeks, or at least three weeks) after reconstitution or suspension. The stability of droxidopa is measured by the level of the major degradant (i.e., dihydroxybenzaldehyde) and the total degradation. In some embodiments, the droxidopa in the liquid vehicle or the suspending vehicle is stable when the level of dihydroxybenzaldehyde is below 0.1%, 0.05%, 0.04%, 0.03%, 0.02%, or 0.01%. In some embodiments, the droxidopa in the liquid vehicle or the suspending vehicle is stable when the level of the total degradation is below 1%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%.
In certain embodiments, the oral dosage form further comprises droxidopa, or a pharmaceutically acceptable salt thereof, in an immediate release form. The composition or suspension can include ≤14% or ≥56% of the total amount of droxidopa, or a pharmaceutically acceptable salt thereof, in the dosage form in an immediate release form. In some embodiments, the amount of droxidopa, or a pharmaceutically acceptable salt thereof, in an immediate release form is 1% to 14%, 2% to 14%, 3% to 14%, 4% to 14%, 5% to 14%, 6% to 14%, 7% to 14%, 8% to 14%, 9% to 14%, 10% to 14%, 11% to 14%, 12% to 14%, 1% to 13%, 2% to 13%, 3% to 13%, 4% to 13%, 5% to 13%, 6% to 13%, 7% to 13%, 8% to 13%, 9% to 13%, 10% to 13%, 11% to 13%, 1% to 12%, 2% to 12%, 3% to 12%, 4% to 12%, 5% to 12%, 6% to 12%, 7% to 12%, 8% to 12%, 9% to 12%, 10% to 12%, 1% to 11%, 2% to 11%, 3% to 11%, 4% to 11%, 5% to 11%, 6% to 11%, 7% to 11%, 8% to 11%, 9% to 11%, 1% to 10%, 2% to 10%, 3% to 10%, 4% to 10%, 5% to 10%, 6% to 10%, 7% to 10%, 8% to 10%, less than 14%, less than 12%, less than 10%, less than 8%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2% or less than 1% of the total weight of droxidopa in the composition or suspension.
In some embodiments, the composition or suspension disclosed herein can comprise droxidopa, or a pharmaceutically acceptable salt thereof, in an immediate release form, in an amount of 20% to 40%, 20% to 35%, 20% to 30%, 25% to 40%, 25% to 35%, 25% to 30%, 30% to 40%, 30% to 35%, or 35% to 40% of the total weight of droxidopa in the composition or suspension.
In some embodiments, the composition or suspension disclosed herein can comprise droxidopa, or a pharmaceutically acceptable salt thereof, in a fast release form, in an amount of 20% to 40%, 20% to 35%, 20% to 30%, 25% to 40%, 25% to 35%, 25% to 30%, 30% to 40%, 30% to 35%, or 35% to 40% of the total weight of droxidopa in the composition or suspension.
In another aspect, a pharmaceutical kit is disclosed herein. The kit can comprise any of the solid pharmaceutical compositions disclose herein (e.g., a multi-particulate packaged in a sachet, a bottle or a packet) and a liquid vehicle for reconstituting or suspending the solid composition into an oral liquid dosage form, e.g., a solution, a suspension, or an emulsion dosage form. The liquid vehicle can be a suspending vehicle. In some embodiments, the liquid dosage form produced can have a pH<7.0. In some embodiments, the liquid dosage form produced can have a pH from 7.0 to 8.0, or from 7.0 to 9.0. In some embodiments, the pH is less than 5.0. In some embodiments, the pH is from about 2.0 to about 5.0, or from about 3.0 to about 5.0.
The kit can be in the form of a capped bottle in which the composition is stored in a sealed compartment within the cap of the bottle and the liquid vehicle is stored in the bottle. In some embodiments, the cap of the bottle stores a solid dosage form (e.g., a multi-particulate) comprising droxidopa, or a pharmaceutically acceptable salt thereof, in a sealed compartment within the cap of the bottle. In some embodiments, the liquid vehicle (e.g., a suspending vehicle) is stored in the bottle. In some embodiments, the sealed compartment within the cap of the bottle is unsealed and the solid dosage form is combined with the liquid vehicle. In some embodiments, the solid dosage form comprises two or more types of multi-particulate pellets and the liquid vehicle is a suspending vehicle. In some embodiments, some excipients of the liquid vehicle (e.g., a suspending agent or a gel forming polymer) can be stored in a solid form in the kit.
In some embodiments, the solid dosage form (e.g., a multi-particulate) is stored in a container (e.g., a sachet), and a patient can open the container, mix the solid dosage with water or a beverage, or sprinkle the solid dosage on food, for oral consumption.
In certain aspects of the disclosure, the kit comprises a single dose or multiple doses, for example 2, 3, 4, 5, 6, 7, 8, or more doses. The kit (e.g., a single bottle) can be prepared to provide a single daily dosage amount or the daily dosage amount for multiple days, for example at least 3, 4, 5, 6, or 7 days. In some embodiments, the liquid dosage form is a suspension that is stable at room temperature or 4° C. for at least 7 days, 10 days, 14 days, or 21 days.
Active agent release from a pharmaceutical formulation can be analyzed in various ways. One exemplary test is in vitro dissolution. A dissolution profile is a plot of the cumulative amount of active agent released from a formulation as a function of time. A dissolution profile can be measured utilizing the Drug Release Test <724>, which incorporates standard test USP 39 (Test <711>). A profile is characterized by the test conditions selected such as, for example, apparatus type, shaft speed, temperature, volume, and pH of the dissolution medium. More than one dissolution profile may be measured. For example, a first dissolution profile can be measured at a pH level approximating that of the stomach, and a second dissolution profile can be measured at a pH level approximating that of one point in the intestine or several pH levels approximating multiple points in the intestine.
For example, for the currently marketed droxidopa dosage forms, the U.S. FDA suggests evaluation of droxidopa release characteristics and dissolution profiles in 900 mL of 0.1 N HCl, equilibrated at 37° C.±0.5° C. using a basket method (USP Apparatus 1) at 100 rpm with sampling times of 5, 10, 15, 20, 30 minutes. Other conditions, such as different pH, extended dissolution time for up to 24 hrs or different apparatus may be used as known in the art. Sample aliquots can be taken at different time intervals and analyzed by high performance liquid chromatography.
Dissolution profile can be measured under other conditions, for example: 900 mL of 0.1 N HCl for 0-2 hours and Phosphate Buffer (pH 6.8) for 2-8 hours or 2-14 hours using an USP II (Paddle) apparatus.
Alternatively, active agent release from a pharmaceutical formulation can be determined in a pharmacokinetics study. Design of such a pharmacokinetics study is within the skill of practitioners in the art.
The extended release droxidopa dosage forms when orally administered once daily to a subject, provide a droxidopa plasma level in the subject of about 0.5 μg/mL to 5 μg/mL for a duration of about 4 to 24 hour or about 4 to 16 hours after oral administration to the subject.
In some embodiments, the composition or suspension disclosed herein releases substantially all of the active agent in about 6, 7, or 8 hours post administration. In some embodiments, the composition or suspension disclosed herein provides only one Cmax and the Cmax is at about 1 to 5 hours post administration.
In another aspect, a method of treating a subject is disclosed. The method can comprise orally administering an effective amount of a droxidopa liquid dosage form disclosed herein or a solid droxidopa composition herein to a subject in need of treatment of a disease or disorder. The disease or disorder can be hypotension (for example neurogenic orthostatic hypotension (nOH) or intradialytic hypotension), a symptom of Parkinson's disease (e.g., orthostatic hypotension, postural instability (US20130197090)), Down's syndrome (WO2010132128), a demyelinating disease (U.S. Pat. No. 8,580,776), Alzheimer's disease (U.S. Pat. No. 8,580,776), an attention deficit disorder (U.S. Pat. No. 8,383,681), hypersomnia (US2012010293), pain associated with fibromyalgia (U.S. Pat. No. 8,008,285), motor paralysis (U.S. Pat. No. 5,656,669), motor aphasia (U.S. Pat. No. 5,656,669), urinary incontinence (U.S. Pat. No. 5,266,596), dementia (U.S. Pat. No. 4,690,949), antidiuresis (U.S. Pat. No. 4,647,587), postural tachycardia syndrome (US20150374691), tauopathy (US2014249180), fatigue (US2013116286), headaches (US2006035976), neurological deficits or neuronal death induced by brain ischemia (US2001007856), intracranial hypertension or cerebral edema (US2001007856), cancer (WO2016062272), a bacterial infection (WO2016123063), to induce or facilitate micturition (WO2015127558), nasal congestion (WO2005084330), or pain (e.g., acute or chronic) (WO2004032844). Preferably the disease or disorder is hypotension or a symptom of Parkinson's disease. The administering can be once or twice daily, and can occur with the subject in a supine position. In some embodiments, the total daily dose of droxidopa administered to the subject is 100 mg to 1800 mg or about 100 mg to about 3000 mg.
The compositions or oral dosage forms of the present disclosure comprising droxidopa, or a pharmaceutically acceptable salt thereof, can be used to treat or reduce the incidence of a disorder including at least one of: orthostatic hypotension; postural orthostatic tachycardia syndrome (POTS); dysautonomia; symptoms of chronic orthostatic hypotension corresponding to autonomic failure associated with Bradbury-Eggleston syndrome, Shy-Drager syndrome, diabetes mellitus disease, and Parkinson's disease; and retrograde ejaculation. In some embodiments, the compositions or oral dosage forms of the present disclosure can be used to treat orthostatic hypotension in a subject suffering from Parkinson's disease. In some embodiments, the oral dosage form, pharmaceutical composition, or formulation of the present disclosure can be used to treat a subject suffering from or at risk of suffering from postural orthostatic tachycardia syndrome (POTS).
In certain aspects, the method is directed to treating a subject suffering from or at risk of suffering from orthostatic hypotension due to autonomic failure comprising administering an effective amount of a composition or oral dosage form disclosed herein to the subject.
In certain aspects, the method is directed to treating a subject having Parkinson's disease or postural orthostatic tachycardia syndrome (POTS) who suffers from or is at risk of suffering from orthostatic hypotension comprising administering an effective amount of a composition or oral dosage form disclosed herein to the subject.
In some embodiments, the subject is 10-50 years old, 10-25 years old, e.g., 13-18 years old, 13-21 years old, or 13-25 years old. In some embodiments, the subject is male or female. In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the subject is female, aged 13-25 years old and suffers from POTS. In some embodiments, the subject suffers from Parkinson's disease. In some embodiments, the subject suffers from early-onset Parkinson's disease (e.g., is 50 years old or younger). In some embodiments, the subject is older than 50 years.
The method of treatment can include administering a single dose of a composition or oral dosage form disclosed herein to a subject. In certain embodiments, the composition or oral dosage form comprises droxidopa, or a pharmaceutically acceptable salt thereof, in an amount of about 100 mg to about 3000 mg, about 200 mg to about 3000 mg, about 300 mg to about 3000 mg, about 400 mg to about 3000 mg, about 500 mg to about 3000 mg, about 600 mg to about 3000 mg, about 700 mg to about 3000 mg, about 800 mg to about 3000 mg, about 900 mg to about 3000 mg, about 1000 mg to about 3000 mg, about 1500 mg to about 3000 mg, about 2000 mg to about 3000 mg, about 100 mg to about 1800 mg, about 200 mg to about 1800 mg, about 300 mg to about 1800 mg, about 400 mg to about 1800 mg, about 500 mg to about 1800 mg, about 600 mg to about 1800 mg, about 700 mg to about 1800 mg, about 800 mg to about 1800 mg, about 900 mg to about 1800 mg, about 500 mg to about 1200 mg, about 600 mg to about 1000 mg, or about 800 mg to about 1000 mg. In some embodiments, the composition or oral dosage form comprises droxidopa, or a pharmaceutically acceptable salt thereof, in an amount of about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, about 2500 mg, about 2600 mg, about 2700 mg, about 2800 mg, about 2900 mg, or about 3000 mg. In some embodiments, the composition or oral dosage form disclosed herein is administered once or twice daily.
In some embodiments, a single dose can be administered to effectively raise blood pressure in a subject and maintain the blood pressure in the subject during an extended release period. A single dose can include the active agent in an amount in milligrams of about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, or a range between about 100 mg to about 1800 mg or about 100 mg to about 3000 mg, between about 300 mg to about 1800 mg, between about 500 mg to about 1500 mg, between about 500 mg to about 1200 mg, about 600 to about 1200 mg, or between about 800 mg to about 1000 mg.
In some embodiments, the composition or oral dosage form is a liquid dosage (e.g., a suspension or emulsion) and the dosage can be titrated to an effective level for the subject. A subject can start with an initial dose of the active and the subsequent doses can be adjusted based on the subject's response to the initial dose. Dose titration can be conveniently achieved for the liquid dosage form by adjusting the volume of oral suspension to be administered to the subject. In some embodiments, the volume of the liquid dosage form (e.g., a solution, a suspension, or an emulsion) to be administered to a subject is about 5 mL to about 100 mL (e.g., about 10 mL to about 100 mL, about 10 mL to about 75 mL, about 30 mL to about 60 mL) per dose.
In some embodiments, the methods of the present application are directed to administering a composition or oral dosage form disclosed herein to a subject to maintain the subject's blood pressure in a clinically acceptable range throughout the day.
The method can include administering the single dose to the subject according to any aspect of the composition or oral dosage form described herein. For example, the method can include administering the single dose to the subject in the form of extended release multi-particulates suspended in a liquid vehicle.
In some embodiments, the method can include administering the single dose to the subject such that the extended release of the active agent into the subject's plasma over the extended release period is characterized by an extended release rate. The method may include administering the single dose to the subject such that greater than about 50% (w/w) of the active agent in the pharmaceutical composition is released to the subject over the extended release period. The extended release period can be, in hours, at least one of, or at least about one of: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 hours, e.g., about 12 hours, or a range between any two of the preceding values, for example, of between about 4 hours and about 12 hours, between 6 hours to 12 hours, between 8 hours to 12 hours, between 8 hours to 14 hours, or between 8 hours to 16 hours.
In some embodiments, the composition or oral dosage form described herein is administered once or twice daily to a subject in need thereof. The dose administered can be sufficient to obtain a suitable therapeutic response in the subject.
A variety of processes can be used to produce the extended release multi-particulates comprising droxidopa and the release controlling agent. Exemplary processes include hot melt extrusion, melt granulation, extrusion spheronization, direct pelletization, spray drying, and spray congealing.
Generally, melt-granulation techniques involve melting a normally solid release controlling agent, e.g. a wax or a lipophilic compound, and incorporating a powdered active agent therein. The release controlling agent can be pre-heated to a molten state and then mixed with the dry pre-blend of the remaining matrix ingredients. Alternatively, the release controlling agent can be mixed with the dry pre-blend and the entire mass is then heated to melt the release controlling agent. The mixing should be sufficient to homogenously disperse the thy pre-blend into the molten binder. The mixture is then allowed to cool and the mixture can be ground or milled and screened to the desired size. The ground or milled granulate may be mixed with an optional lubricant or other processing aid. The processing aid can include, for example, hydrophobic colloidal silicon dioxide (such as CAB-O-SIL® M5). Hydrophobic silicon dioxide may be used in amounts of less than or equal to about 0.5 wt %, but individual formulations can be varied as required. The blend of the granulate and the processing aids, if any, may be optionally compressed into mini-tablets and then optionally coated.
The preparation of a suitable melt-extruded matrix according to the present invention may, for example, include the steps of blending the active agent, together with a release-controlling agent and optionally a binder material to obtain a homogeneous mixture. The homogeneous mixture is then heated to a temperature sufficient to at least soften the mixture sufficiently to extrude the same. The resulting homogeneous mixture is then extruded, e.g., using a twin-screw extruder, to form strands. The extrudate is preferably cooled and cut into multiparticulates by any means known in the art. The strands are cooled and cut into multiparticulates. The multiparticulates are then divided into unit doses. The extrudate preferably has a diameter of from about 0.1 to about 5 mm and provides controlled release of the therapeutically active agent for a time period of from about 4 to about 24 hours or about 4 to about 16 hours.
Extrusion-spheronization typically begins with damp wet mass which can be extruded with a twin screw extruder in to wet extrudes. The wet extrudes are spheronized in a marumerizer at a predetermined speed. The extruded cylindrically shaped extrudates are gradually transformed into spherical shapes.
There are few techniques available that can be used to directly form pellets. One of the examples of these techniques is rotor granulation. With this advanced technology, pellets with spherical shape, smooth surface and uniform particle size are generated. Physical properties of the pellets can be controlled through ingredients' properties and process parameters.
Spray drying and spray congealing, known as globulation processes, involve atomization of hot melts, solutions, or suspensions to generate spherical particles or pellets. During spray drying, drug entities in solution or suspension is sprayed, with or without excipients, into a hot air stream to generate dry and highly spherical particles. As the atomized droplets come in contact with hot air, evaporation of the application medium is initiated. This drying process continues through a series of stages where the viscosity of the droplets constantly increases until finally almost the entire application medium is driven off and solid particles are formed. Generally, spray-dried pellets tend to be porous.
During spray congealing, a drug substance is allowed to melt, disperse, or dissolve in hot melts of waxes, fatty acids, etc., and sprayed into an air chamber where the temperature is below the melting temperatures of the formulation components, to provide under appropriate processing conditions spherical congealed pellets.
The multiparticulates can optionally be coated with a protection layer, such as a moisture protection layer. The terms “protection layer” and “protective layer” are used interchangeably herein. The most common method used for the application of coating onto multiparticulates is air suspension coating. Other methods include compression coating, solvent evaporation, coacervation, and interfacial complexation.
In some embodiments, the multi-particulate of the disclosure is prepared by direct pelletization, e.g., using rotor granulation. Characteristics of the pellets formed from the direct pelletization process included one or more of spherical shape, smooth surfaces, broad drug load (<1-90%), high density, and/or uniform and small particle size (e.g., less than 400 μm).
In another aspect, a method of making an oral liquid dosage form is disclosed. The method comprises mixing any of the solid droxidopa compositions disclosed herein with a liquid vehicle to produce a liquid dosage form. The liquid dosage form can be a suspension or an emulsion. The liquid dosage form can have a pH<7.0, <6.5, <6.0, <5.5, or <5.0. The method can further comprise breaking a seal of a compartment in a bottle in which the solid droxidopa composition is stored to release the composition into the liquid vehicle.
In this specification and claims that follow, references will be made to a number of terms which shall be defined to have the following meanings.
The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term “or” means “and/or”. The terms “comprising”, “having”, “including”, and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”).
A “dosage form” means a unit of administration of an active agent. Examples of dosage forms include tablets, mini-tablets, capsules, suspensions, solutions, liquids, emulsions, bottles, sachets, or packets, and the like.
An “active agent” means a compound, element, or mixture that when administered to a patient, alone or in combination with another compound, element, or mixture, confers, directly or indirectly, a physiological effect on the patient. The indirect physiological effect may occur via a metabolite or other indirect mechanism. In some embodiments, the active agent is droxidopa.
“Dosing regimen” means the dose of an active agent taken at a first time by a patient and the interval (time or symptomatic) at which any subsequent doses of the active agent are taken by the patient. The additional doses of the active agent can be different from the dose taken at the first time.
A “dose” means the measured quantity of an active agent to be taken at one time by a patient.
“Droxidopa” as used herein refers to droxidopa or a pharmaceutically acceptable salt thereof.
“Droxidopa therapy” refers to medical treatment of a symptom, disorder, or condition by administration of droxidopa. Droxidopa therapy can be considered optimal when effective plasma levels are reached when required. In addition, peak plasma values (Cmax) should be as low as possible while still maintaining an effective plasma level throughout the day so as to reduce the incidence and severity of possible side effects.
The term “effective amount” or “therapeutically effective amount” means an amount effective, when administered to a patient, to provide any therapeutic benefit. A therapeutic benefit may be an amelioration of symptoms, e.g., an amount effective to decrease the symptoms of acute gouty arthritis, for example pain associated with an attack of acute gouty arthritis. The amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. In certain circumstances a patient may not present symptoms of a condition for which the patient is being treated. A therapeutically effective amount of an active agent may also be an amount sufficient to provide a significant positive effect on any indicium of a disease, disorder, or condition, e.g. an amount sufficient to significantly reduce the severity of hypotension. A significant effect on an indicium of a disease, disorder, or condition is statistically significant in a standard parametric test of statistical significance, for example Student's T-test, where p<0.05.
In some embodiments, an effective amount or therapeutically effective amount of droxidopa can be an amount of about 100 mg per day to about 1800 mg or about 100 mg to about 3000 mg per day, about 300 mg to about 1800 mg per day, or about 500 mg to about 1800 mg per day.
“Efficacy” means the ability of an active agent administered to a patient to produce a therapeutic effect in the patient.
A “liquid vehicle” as used herein means a solution or a suspension that can be combined with a solid dosage form comprising an active agent for delivery of the active agent to a subject. In some embodiments, the liquid vehicle is a suspending vehicle. In some embodiments, the liquid vehicle (e.g., suspending vehicle) can be an aqueous vehicle or a nonaqueous vehicle. Examples of aqueous vehicles include, e.g., water and a buffered solution. Examples of nonaqueous vehicles include, e.g., mixture of alcohol with aqueous vehicle.
An “oral dosage form” means a unit dosage form for oral administration.
A “patient” means a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition, such as a disease or disorder, prophylactic or preventative treatment, or diagnostic treatment. In some embodiments the patient is a human patient.
As used herein, the terms “pH controlling agent,” “pH modifier,” and “buffering agent” are used interchangeably, unless indicated otherwise. Examples of a pH controlling agent, a pH modifier, or a buffering agent include pharmaceutically acceptable buffering systems, acids having suitable pKa and/or their salts, for example citric acid, citrate salts, tartaric acid, tartarate salts, succinic acid, succinate salts, acetic acid, acetate salts, fumaric acid, and fumarate salts. Inorganic acids can also be used, including hydrochloric or sulfuric acid.
“Pharmaceutically acceptable” means that which is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
“Pharmaceutically acceptable salts” includes derivatives of droxidopa, wherein the droxidopa is modified by making acid or base addition salts thereof, and further refers to pharmaceutically acceptable solvates, including hydrates, and co-crystals of such compounds and such salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid addition salts of basic residues such as amines; alkali or organic addition salts of acidic residues; and the like, and combinations comprising one or more of the foregoing salts. The pharmaceutically acceptable salts include non-toxic salts and the quaternary ammonium salts of the droxidopa. For example, non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like; and alkaline earth metal salts, such as calcium salt, magnesium salt, and the like, and combinations comprising one or more of the foregoing salts. Pharmaceutically acceptable organic salts includes salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH2)n-COOH where n is 0-4, and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, and the like; and amino acid salts such as arginate, asparginate, glutamate, and the like; and combinations comprising one or more of the foregoing salts; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′ dibenzylethylenediamine salt, and the like; and amino acid salts such as arginate, asparginate, glutamate, and the like; and combinations comprising one or more of the foregoing salts. All forms of such derivatives of droxidopa are contemplated herein, including all crystalline, amorphous, and polymorph forms.
“Pharmacokinetic parameters” describe the in vivo characteristics of an active agent (or a metabolite or a surrogate marker for the active agent) over time, such as plasma concentration (C), Cmax, Cn, C24, Tmax, and AUC. “Cmax” is the measured plasma concentration of the active agent at the point of maximum, or peak, concentration. “Cmin” is the measured plasma concentration of the active agent at the point of minimum concentration. “Cn” is the measured plasma concentration of the active agent at about n hours after administration. “C24” is the measured plasma concentration of the active agent at about 24 hours after administration. The term “Tmax” refers to the time at which the measured plasma concentration of the active agent is the highest after administration of the active agent. “AUC” is the area under the curve of a graph of the measured plasma concentration of an active agent vs. time, measured from one time point to another time point. For example AUC0-t is the area under the curve of plasma concentration versus time from time 0 to time t, where t can be the last time point with measurable plasma concentration for an individual formulation. The AUC0-∞ or AUC0-INF is the calculated area under the curve of plasma concentration versus time from time 0 to time infinity.
The term “subject” includes any human or non-human animal. For example, the methods and compositions disclosed herein can be used to treat a subject having Parkinson's disease. In a particular embodiment, the subject is a human.
The terms “treating” and “treatment” mean implementation of therapy with the intention of reducing in severity or frequency symptoms, elimination of symptoms or underlying cause, prevention of or reducing the risk of the occurrence of symptoms or their underlying cause, and improvement or remediation of damage.
The terms “administer,” “administering,” “administered” or “administration” refer to any manner of providing an active agent (such as, droxidopa or a pharmaceutically acceptable salt thereof) to a subject or patient. Routes of administration can be accomplished through any means known by those skilled in the art. Such means include oral, buccal, intravenous, subcutaneous, intramuscular, transdermal, and inhalation.
The term “fast release” as used herein refers to a pharmaceutical formulation that releases the active agent contained therein relatively fast, e.g., release of the drug starts within about 15 minutes to 2 hours after the start of an in vitro dissolution test. In some embodiments, the fast release pharmaceutical formulation comprises an immediate release delivery system.
The term “immediate-release” refers to a pharmaceutical formulation characterized by conventional or non-modified release of the active agent immediately after drug administration. In some embodiments, immediate release means greater than or equal to about 75% of the active agent is released within two hours of administration, specifically within one hour of administration.
As used herein, the term “extended release” refers to a pharmaceutical formulation that provides for the gradual release of an active agent over an extended period of time. “Extended-release” includes the release of the active agent at such a rate that blood (e.g., plasma) levels are maintained within a therapeutic range for at least about 4 hours, for about 4 to about 24 hours, about 4 to about 16 hours, or about 6 to about 10 hours. The term steady-state means that a plasma level for a given active agent has been achieved and which is maintained with subsequent doses of the drug at a level which is at or above the minimum effective therapeutic level for a given active agent.
The modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (e.g., includes the degree of error associated with measurement of the particular quantity). The notation “+10%” means that the indicated measurement can be from an amount that is minus 10% to an amount that is plus 10% of the stated value.
“Optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event occurs and instances where it does not. Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
The following example are merely illustrative of the compositions and methods disclosed herein and are not intended to limit the scope hereof.
A variety of processes can be used to produce the extended release multi-particulates comprising droxidopa and a non-polymeric release controlling material. Exemplary processes include hot melt extrusion, melt granulation, extrusion spheronization, direct pelletization, spray congealing and wax coating. Schematic flow charts for manufacture of extended release multi-particulates via each of these processes are shown in
Extended release multi-particulates may also comprise non-release controlling agents such as binders, wetting agents, lubricants, protective coating agents, and surfactants. These excipients are not used to control the drug release, but to improve flowability, stabilize the multi-particulates, minimize premature drug release prior to administration. For example, extended release multi-particulates may be coated with a protective polymer, which is used to minimize premature drug release in the suspension before administration and will dissolve once it is administered.
A protective coating may be applied to the above extended release multi-particulates so that there is no drug release for a period of time, e.g., at least 15 min. An example of the formulation is shown in Table 4 below. The multi-particulates can be administered as a suspension.
Extended release granules can be blended with excipients such as diluents, lubricants, and flow aids, and compressed into extended release mini-tablets with a diameter ranging between 1.0-3.0 mm. Any of the extended release multi-particulates disclosed herein or exemplified above can be used. Table 5 shows an example of extended release multi-particulates.
Extended release droxidopa multi-particulates are packaged in the cap and a suspending vehicle is filled in the bottle. When opening the bottle, the multi-particulates are released from the cap and fall into the bottle with the suspending vehicle. The suspending vehicle may comprise water, suspending agents, sweeteners, stabilizers, preservatives, coloring agents, surfactants, and flavoring agents. Any of the extended release multi-particulates disclosed herein or exemplified above can be used in these dosage forms. An extended release multi-particulate solid formulation and a suspending vehicle formulation, which can be combined in a bottle to form a suspension, is shown in shown in Table 6.
The suspending vehicle may also comprise an alcohol, e.g., ethanol, as shown in Table 7.
The extended release multi-particulates are coated to prevent drug release in a ready-to-use suspension. Any of the extended release multi-particulates disclosed herein or exemplified above can be used in this dosage form.
A quantity of extended release multi-particulates suitable for a single dose or for multiple doses are filled into a sachet or packet.
Use as a sprinkle.
The sachet is opened and the extended release multi-particulates are sprinkled on food or a beverage for oral consumption.
The contents of a single dose sachet is mixed with a suspending vehicle and reconstituted into a suspension at the time of oral administration.
The contents of a multi-dose sachet is mixed with a suitable volume of suspending vehicle including a preservative and reconstituted into a suspension for oral administration over a period of at least a week.
The suspending vehicle is optionally provided with the sachet as shown in Table 10.
Table 11 shows droxidopa solubility at room temperature at pH 1.2, 3.0, 4.5, 5.5 and 6.8.
Droxidopa is stable in acidic solution, but degrades in neutral or alkaline conditions. Saturated droxidopa in citric acid solution (pH 2.5) or in citrate buffer (pH 4.0) was found to be stable at room temperature over 24 days. When citric acid was present with the drug in solid state, e.g. powder or uncoated granules, droxidopa became unstable under accelerated conditions 70° C./75% RH. When these droxidopa granules/pellets were coated with a protective layer, and blended with citric acid, the drug degradation was reduced.
The effect of pH modifiers or buffering agents on certain liquid dosage forms was tested.
Droxidopa was dissolved in 5 diluents at different pH and stored at room temperature for 24 or 48 hours in sealed glass containers. All solutions were prepared at a nominal concentration of 0.5 mg/ml. Percent degradation was determined by ultra-performance liquid chromatography (UPLC) on a Waters ACQUITY UPLC with a photodiode array (PDA) detector using a Waters ACQUITY BEH C18 1.7 um 2.1×50 mm column. Run conditions for the analyses were as follows:
Mobile phase A: 50 mM sodium phosphate pH 3.0
Mobile phase B: Acetonitrile
Detection wavelength: 279 nm
Flow: 0.5 ml/min
Column temperature: 30 C
Injection volume: 2 μl
Gradient (linear transitions) are shown in Table 12A:
Identification of the known components droxidopa and dihydroxybenzaldehyde was confirmed through retention time and spectral match against pure materials of known identity. Degradation results were quantified as a percent area of degradation peaks versus total area of all degradation/droxidopa peaks. Results for pH 10.0 and pH 12.0 samples were estimated at >90% due to a significant number of peaks present near the retention time of droxidopa.
Table 13A below summarizes stability data for droxidopa after exposure in solutions of varying different pH.
1Dihydroxybenzaldehyde
Saturated solutions of droxidopa were prepared in 3 diluents at different pH and stored at room temperature for up to 24 days in sealed containers. All solutions were prepared with an excess of droxidopa by combining 10 mg droxidopa per ml of diluent. Exposed samples were filtered and degradation as a percent of initial droxidopa amount was determined by ultra-performance liquid chromatography (UPLC) on a Waters ACQUITY UPLC with a photodiode array (PDA) detector using a Waters ACQUITY HSS PFP 1.8 μm 2.1×100 mm column. Run conditions for the analyses were as follows:
Mobile phase A: 50 mM ammonium formate pH 3.0
Mobile phase B: Acetonitrile
Detection wavelength: 279 nm
Flow: 0.5 ml/min
Column temperature: 30 C
Injection volume: 1 μl
Gradient (linear transitions) are shown in Table 12B:
Table 13B below summarizes stability data for droxidopa after exposure in saturated solutions.
1Dihydroxybenzaldehyde
These results show that addition of pH modifiers or buffering agents to the tested liquid dosage forms or one or more components required to reconstitute a solid droxidopa composition to a liquid dosage form can help stabilize the drug.
Examples of suspension formulations with a pH modifier are shown in the Tables 14 and 15 below.
Alternatively, the pH modifier can be included in the extended release multi-particulate. An example extended release multi-particulate form including a pH modifier is shown in the Table 16 below.
The liquid vehicle for reconstituting a solid droxidopa multi-particulate into a liquid dosage form may comprise materials which are in solution form before administration in the body, but once administered undergo gelation in situ to form a gel from which the drug is released in a sustained and controlled manner. The formation of a gel depends on various factors such as temperature modulation, pH change, and the presence of ions. Examples of polymers that can be used in formulations for formation of in situ gels after administration include gellan gum (induced by cations), sodium alginate (induced by cations), xyloglucan (induced by temperature), pectin (induced by calcium cation), chitosan, carbomer (induced by pH), poly(DL-lactic acid), poly(DL-lactide-co-glycolide), and poly-caprolactone.
An exemplary formulation of a dosage form providing in situ gel formation and extended release is shown in Table 17 below.
Furthermore, a pH modifier monosodium citrate was used instead of citric acid and blended with droxidopa granules. Droxidopa was stable for 7 days under accelerated conditions 70° C./75% RH. Another pH modifier sodium bitartrate monohydrate was used the same way and showed similar results. Thus, salt based pH modifiers can be used to improve the stability of the droxidopa.
Ready-to-use suspensions comprising extended release multi-particulates comprising a polymer matrix and a suspending vehicle having a pH<7.0 are made.
Extended release multi-particulates are made by dry blending the drug and polymer and then granulated in a fluidized bed granulator using sufficient granulation fluid to produce a wet granulate that is subsequently dried and screened. The multi-particulates optionally include a protection coating. Examples of extended release multi-particulates are show in Tables 18-20.
Any one of above extended release granule formulations, for example the granules including Hypromellose, is mixed with a suspending vehicle comprising a pH modifier (citric acid or monosodium citrate) to form a ready-to-use suspension having a pH<7.0. An example of a ready-to-use suspension is shown in Table 21.
A pH dependence was also observed in drug release from a droxidopa tablet in dissolution tests. The tested tablet formulation is shown in Table 22 below.
Droxidopa dissolution from the tablets was tested in 900 mL 0.1N HCl or water in a USP II apparatus (paddle) at 37° C. and 50 rpm. The % drug released over time is shown in Table 23.
An extended release droxidopa suspension containing two different types of pellets, pellets I and pellets II, were prepared as shown in Table 24A.
Pellets I included a release controlling agent. Upon exposure to pH 1.2 in stomach, Pellets I started releasing the drug over a short period of time, e.g. up to about 2-3 hrs.
Pellets II included a release controlling agent and a protective coating, protecting the drug from releasing in stomach pH 1.2, but allowing release at about pH 5.5. For example, Eudragit L30-D55 was used to protect the drug from releasing in stomach, and can readily dissolve in small intestine at pH 5.5.
Hydroxypropyl cellulose (HPC) was used as a binder and is compatible with the drug. No significant degradation was observed when HPC was used as a dry binder or added as a binder in solution form. The quantity of HPC used is less than 10% w/w, so it does not control drug release in this formulation.
A pH dependence was observed in drug release in a dissolution test performed with USP Apparatus II (Paddles) at 50 rpm in 745 ml of 0.1 N HCl for 2 hours at 37° C. and USP Apparatus II (Paddles) at 50 rpm in 900 ml of pH 6.8 phosphate buffer for 2-8 hours at 37° C. The dissolution profile (% release over time) is shown in Table 25 and
Alternatively, pellets I were coated with a protective layer which is soluble at pH 5.0 or below and the pH of the suspension can be 7.0 or higher (see Table 24B). The protective layer prevents exposure of the drug to higher pH of the suspension and thus degradation. Upon administration, the protective layer dissolves in stomach and drug is released in the similar manner.
No buffering agent was used for pellet I or pellet II. Instead, the drug release for the formulation was controlled by non-polymeric materials.
Extended release granules with 900 mg droxidopa were prepared by melt granulation process and included the ingredients shown in Table 26.
A dissolution test with the extended release granules was performed with USP Apparatus II (Paddles) at 50 rpm in 745 ml of 0.1 N HCl for 2 hours at 37° C. and USP Apparatus II (Paddles) at 50 rpm in 900 ml of pH 6.8 phosphate buffer for 2-14 hours at 37° C. The dissolution profile (% release over time) is shown in
Extended release mini-tablets with 900 mg droxidopa were prepared by melt granulation and direct compression process and included the ingredients shown in Tables 27 (using wax as the release-controlling agent) and Table 28 (no release controlling agent included).
A dissolution test on the mini-tablets was performed with USP Apparatus II (Paddles) at 50 rpm in 745 ml of 0.1 N HCl for 2 hours at 37° C. and USP Apparatus II (Paddles) at 50 rpm in 900 ml of pH 6.8 phosphate buffer for 2-14 hours at 37° C. No different in dissolution profile was observed for mini-tablets prepared either by melt granulation or by direct compression. The dissolution profile (% release over time) is shown in
Pellets formed by extrusion spheronization process are usually quite limited by the size of the twin-screw screens available. Pellets prepared by extrusion spheronization often have a wide particle size distribution. For an oral extended-release suspension, uniform pellets with a particle size less than 400 μm was desired to avoid a gritty mouth-feel. Further, the four-steps involved in the extrusion spheronization process makes it not economic.
A preferred manufacturing process that could create uniform size pellets with higher drug load was preferred for pellet formation. There were few techniques available that could be used to form such pellets.
An example of a technique for direct pellet formation is rotor granulation. Characteristics of the pellets formed from the direct pelletization process included spherical shape, smooth surfaces, broad drug load (<1-90%), high density, uniform and smaller particle size.
An example of direct pelletization manufacturing process is described as follows: droxidopa was blended with microcrystalline cellulose and a rate-controlling agent in a high shear granulator, and water was sprayed to form a damp mass. The damp mass was then fed into a rotary granulator where the loose agglomerates were densified and spheronized by an orbital motion while additional water was sprayed. Small and uniform pellets were produced and then dried in a fluid bed processor. A portion of the pellets was further coated in a fluid bed processor with a protective layer. Optionally, the rest of the pellets were coated with a moisture protective layer, which dissolved at pH 1.2. These pellets were blended together to form a uniform blend, which can be filled into a sachet or into a cap of a bottle containing a suspending vehicle in the bottle.
As an another example of direct pelletization, droxidopa was blended with microcrystalline cellulose in a high shear granulator, and purified water was sprayed onto the blend to form a damp mass. The damp mass was then fed into a rotary granulator where the loose agglomerates were densified and spheronized by an orbital motion. Small uniform pellets were produced and dried in a fluid bed processor. Extended release pellets were produced by further coating these pellets with a non-polymeric material in a fluid bed processor. Spraying molten wax on drug loaded immediate release pellets formed extended release pellets.
Pulsatile release can be realized by incorporating three different kinds of extended release multi-particulate (e.g., pellets or granules) that each starts releasing the drug at a different time. For example, the first type of multi-particulate (1st pulse) release the drug for a period of about 4 hours. The 2nd type of coated multi-particulate (2nd pulse) will not release any drug until about 4 hours later, but will start to release the drug about 4 hours after the initial administration of the pulsetile release formulation and extends the drug release for 4 hours after the 1st pulse release period. The 3rd type of coated multi-particulate (3rd pulse), will not release the drug until about 8 hours later, but will start to release the drug 8 hours after the initial administration of the pulsetile release formulation and extends the drug release for 4 hours after the 2nd pulse release period and for a total of 12 hours extended release following the initial administration of the pulsetile release formulation.
Extended release granules can be prepared by wet granulation process followed by a melt granulation process. Drug, a filler, and a binder are blended and granulated in a high shear granulator forming wet granules, which are dried in a fluid bed processor. The granules are mixed with a wax, e.g. hydrogenated castor oil and heated up to the temperature above melting point of the wax, then granulated to form extended release granules. These granules can be coated with different levels of coating which start releasing the drug at different pH.
Pulsatile drug release can release equal amount of drug during each pulse (see Table 31 &
Droxidopa pellet suspensions were prepared and stored at room temperature and at refrigerated temperature for up to 21 days in sealed containers. Suspensions included pellets containing 900 mg droxidopa (prepared similarly to pellets I of Formulation II in Example 16: 900 mg droxidopa; 900 mg microcrystalline cellulose; water, q.s.) in 30 ml of a suspending vehicle as shown below. A description of the study is shown in Table 33.
For tested samples, the suspension was centrifuged and the supernatant was diluted 1 to 5 with water. Supernatant of the suspension was analyzed. Degradation as a percentage of droxidopa amount was determined by ultra-performance liquid chromatography (UPLC) on a Waters ACQUITY UPLC with a photodiode array (PDA) detector utilizing 2 methods that covered the range of separation characteristics for potential degradation products.
Method 1: Analysis performed using a Waters Acquity HSS PFP 1.8 μm 2.1×100 mm column. Run conditions for the analyses were as follows:
Mobile phase A: 10 mM ammonium formate adjusted to pH 3.0 with formic acid
Mobile phase B: acetonitrile
Detection wavelength: 279 nm
Flow: 0.5 ml/min
Column temperature: 30° C.
Injection volume: 1 μl
Gradient (linear transitions) are shown in Table 34:
Method 2: Analysis performed using a Waters Acquity BEH Amide 1.7 μm 2.1×50 mm column. Run conditions for the analyses were as follows:
Identification of a known degradation product dihydroxybenzaldehyde was confirmed through retention time and spectral match and quantified against pure material of known identity. Degradation results for unidentified peaks were quantified against a droxidopa standard of known concentration assuming a relative response of 1.
Table 35 below summarizes stability data for droxidopa after exposure in suspended solution.
1Dihydroxybenzaldehyde
These results showed that the presence of a buffering agent (monosodium citrate) stabilized the droxidopa pellet suspension stored at room temperature for at least 21 days.
The compositions and methods disclosed herein include(s) at least the following embodiments (E's):
E1. An extended-release liquid composition for oral administration comprising:
(a) a multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a release controlling agent; and
(b) a liquid vehicle.
E2. The liquid composition of embodiment 1, wherein the release controlling agent is a non-polymeric material, optionally a wax, a lipophilic compound, or a combination thereof.
E3. The liquid composition of embodiment 1 or 2, wherein the liquid vehicle has a pH less than 7.0.
E4. The liquid composition of embodiment 3, wherein the liquid vehicle has a pH of 6.0-7.0, optionally about pH 6.5; or about 2.0-5.0, optionally about pH 4.0.
E5. The liquid composition of any of the preceding embodiments, where the multi-particulate comprises:
(i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and optionally a first release controlling agent; and
(ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a second release controlling agent.
E6. The liquid composition of embodiment 5, wherein the first multi-particulate further comprises a moisture protection layer.
E7. The liquid composition of embodiment 5 or embodiment 6, wherein the first multi-particulate comprises a first release controlling agent, and wherein the first release controlling agent is a non-polymeric material.
E8. The liquid composition of any of embodiments 5 to 7, wherein the second release controlling agent is a non-polymeric material.
E9. The liquid composition of any of embodiments 5 to 8, wherein the second multi-particulate further comprises an enteric layer.
E10. The liquid composition of any of embodiments 5 to 9, wherein the first multi-particulate comprises about 20% to about 40% of the total amount of droxidopa, or a pharmaceutically acceptable salt thereof, in the composition.
E11. The liquid composition of any of embodiments 5 to 10, wherein the second multi-particulate comprises about 60% to about 80% of the total amount of droxidopa, or a pharmaceutically acceptable salt thereof, in the composition.
E12. The liquid composition of any of embodiments 5 to 11, wherein the second multi-particulate further comprises a pH controlling agent.
E13. The liquid composition of embodiment 12, wherein the pH controlling agent is present in an amount sufficient to provide pH independent release of droxidopa from the second multi-particulate.
E14. The liquid composition of embodiment 12 or 13, wherein the pH controlling agent is citric acid, tartaric acid, or a salt thereof.
E15. The liquid composition of embodiment 13 or 14, wherein the pH controlling agent is a salt of citric acid or tartaric acid.
E16. The liquid composition of any of embodiments 1 to 15, wherein the liquid vehicle comprises a pH modifier.
E17. The liquid composition of embodiment 16, wherein the pH modifier is citric acid, tartaric acid, or a salt thereof.
E18. The liquid composition of embodiment 17, wherein the pH modifier is a salt of citric acid or tartaric acid.
E19. The liquid composition of any of embodiments 16 to 18, wherein the pH modifier is present in an amount sufficient to increase stability of droxidopa in the composition.
E20. The liquid composition of any of embodiments 1 to 19, wherein the liquid vehicle further comprises a suspending agent.
E21. The liquid composition of any of embodiments 5 to 20, wherein the first multi-particulate is capable of releasing droxidopa, or a pharmaceutically acceptable salt thereof, at a pH of less than about 1.5, and the second pellet is capable of releasing droxidopa, or a pharmaceutically acceptable salt thereof, at a pH of about 5.5.
E22. The liquid composition of any of embodiments 5 to 21, wherein the first multi-particulate is in the form of a pellet, a granulate, or a mini-tablet; and the second multi-particulate is in the form of a pellet, a granulate, or a mini-tablet.
E23. The liquid composition of any of the preceding embodiments, wherein the composition is a suspension or an emulsion.
E24 An extended-release suspension for oral administration comprising
an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a release-controlling agent; and
a suspending vehicle,
wherein the suspension has a pH<7.0.
E25. The suspension of embodiment 24, wherein the release-controlling agent comprises a polymer, a non-polymeric material, or a combination thereof.
E26. The suspension of embodiment 24 or 25, wherein the release-controlling agent comprises a non-polymeric material.
E27. The suspension of any one of embodiments 24 to 27, wherein the release-controlling agent comprises a wax, a lipophilic compound, or a combination thereof.
E28. The suspension of embodiment 24 or 25, wherein the release-controlling agent comprises a polymer.
E29. The liquid composition or the suspension of any of the preceeding embodiments, further comprising droxidopa, or a pharmaceutically acceptable salt thereof, in an immediate release form.
E30. The liquid composition or the suspension of any of the preceeding embodiments, further comprising ≤14% or ≥56% of the total amount of droxidopa, or a pharmaceutically acceptable salt thereof, in the liquid composition or the suspension in an immediate release form.
E31. The liquid composition or the suspension of any of the preceding embodiments, wherein the liquid vehicle or suspending vehicle is an aqueous vehicle.
E32. The liquid composition or the suspension of any of the preceding embodiments, wherein the liquid vehicle or suspending vehicle is a pharmaceutically acceptable nonaqueous vehicle.
E33. The liquid composition or the suspension of embodiment 32, wherein the pharmaceutically acceptable nonaqueous vehicle comprises glycerin, propylene glycol, or a combination thereof.
E34. The liquid composition or the suspension of any of the preceding embodiments, wherein the total amount of droxidopa, or a pharmaceutically-acceptable salt thereof, in a single 5 mL to 100 mL dose of the liquid composition or the suspension is about 100 mg to about 3000 mg, optionally about 100 mg to about 1800 mg.
E35. The liquid composition or the suspension of any of the preceding embodiments, wherein the total amount of droxidopa, or a pharmaceutically-acceptable salt thereof, in a 5 mL dose of the liquid composition or the suspension is about 100 mg to about 1800 mg.
E36. The liquid composition or the suspension of any of the preceding embodiments, wherein the total amount of droxidopa, or pharmaceutically-acceptable salt thereof, in a single 10 mg to 100 mL dose of the liquid composition or suspension is about 300 mg to about 1500 mg.
E37 The liquid composition or the suspension of any of the preceding embodiments, wherein the total amount of droxidopa, or pharmaceutically-acceptable salt thereof, in a single 10 mL to 100 mL dose of the composition or suspension is 300 mg to 500 mg, 600 mg to 1000 mg, or 1000 mg to 1500 mg.
E38. The liquid composition or the suspension of any of the preceding embodiments, wherein the liquid composition or the suspension provides a droxidopa plasma level in a subject of about 0.5 μg/mL to 5 μg/mL for a duration of about 4 to 24 hour or about 4 to 16 hours after oral administration of the suspension to the subject.
E39. The liquid composition or the suspension of any of the preceding embodiments, comprising two or more types of extended-release multi-particulates comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, wherein each type of multi-particulates has a different extended release profile for droxidopa, or the pharmaceutically acceptable salt thereof.
E40. The liquid composition or the suspension of embodiment 39, wherein the two or more types of extended-release multi-particulates provides: a first release of droxidopa, or the pharmaceutically acceptable salt thereof, in the stomach and a second release of droxidopa, or the pharmaceutically acceptable salt thereof, is in the small intestine.
E41. The liquid composition or the suspension of any of the preceding embodiments, wherein the liquid composition or the suspension is packaged to provide a daily dosage amount of droxidopa, or the pharmaceutically acceptable salt thereof, of about 100 mg to about 3000 mg or about 100 mg to about 1800 mg for a single day.
E42. The liquid composition or the suspension of any of the preceding embodiments, wherein the liquid composition or the suspension is packaged to provide per package a daily dosage amount of droxidopa, or the pharmaceutically acceptable salt thereof, of about 100 mg to about 3000 mg or about 100 mg to about 1800 mg for n days, preferably n is at least 3, 4, 5, 6, or 7.
E43. The liquid composition or the suspension of any of the preceding embodiments, wherein the multi-particulate is combined with the liquid vehicle or suspending vehicle less than 7 days prior to oral administration.
E44. The liquid composition or the suspension of any of the preceding embodiments, wherein the multi-particulate is coated with a protection layer, optionally a moisture protection layer.
E45. The liquid composition or the suspension of embodiment 44, wherein the protection layer comprises a cationic methacrylate copolymer.
E46. The liquid composition or the suspension of any of the preceding embodiments, wherein the droxidopa, or the pharmaceutically acceptable salt thereof, is stable for at least 7 days, optionally three weeks, after suspension in the liquid vehicle or the suspending vehicle.
E47. A solid pharmaceutical composition for oral administration comprising an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a non-polymeric release-controlling agent.
E48. The solid composition of embodiment 47, in the form of a capsule filled with the extended-release multi-particulate.
E49. The solid composition of embodiment 47 or 48, wherein the extended-release multi-particulate further comprises a pH-controlling agent, preferably the pH controlling agent can maintain the pH of a liquid dosage form comprising the solid composition and a liquid vehicle at a pH of <7.0.
E50. The solid composition of any one or more of embodiments 47 to 49, wherein the release-controlling agent comprises a wax, a lipophilic compound, or a combination thereof.
E51. The solid composition of embodiment 50, wherein the wax comprises bees wax or carnauba wax.
E52. The solid composition of embodiment 50, wherein the lipophilic compound comprises a lipid, a fat, a hydrogenated vegetable oil, or a combination thereof.
E53. The solid composition of embodiment 52, wherein the lipophilic compound comprises glycerol behenate, glyceryl monostearate, glyceryl palmitostearate, stearyl alcohol, hydrogenated castor oil, or a combination thereof.
E54. The solid composition of any one of embodiments 47 to 53, further comprising a lubricant and/or a glidant.
E55. The solid composition of any one of embodiments 47 to 54, wherein the multi-particulate is coated with a protection layer, optionally a moisture protection layer.
E56. The solid composition of embodiment 55, wherein the protection layer comprises a cationic methacrylate copolymer.
E57. The solid composition of any one of embodiments 47 to 56, further comprising droxidopa, or a pharmaceutically acceptable salt thereof, in an immediate release form.
E58. The solid composition of any one of embodiments 47 to 57, further comprising ≤14% or ≥56% of the total amount of droxidopa, or a pharmaceutically acceptable salt thereof, in the solid composition in an immediate release form.
E59. The solid composition of any one of embodiments 47 to 58, providing a droxidopa plasma level in a subject of about 0.5 μg/mL to 5 μg/mL for a duration of about 4 to 16 hours after oral administration of the solid composition to the subject.
E60. The solid composition of any one of embodiments 47 to 59, comprising two or more extended-release types of multi-particulates comprising droxidopa, or a pharmaceutically acceptable salt thereof, wherein each type of multi-particulate has a different extended release profile for droxidopa, or the pharmaceutically acceptable salt thereof.
E61. The solid composition of any one of embodiments 47 to 60, wherein the composition is packaged to provide per package a daily dosage amount of droxidopa, or the pharmaceutically acceptable salt thereof, of about 100 mg to about 3000 mg or about 100 mg to about 1800 mg.
E62. The solid composition of any one of embodiments 47 to 61, wherein the solid composition is packaged to provide per package a dosage amount of droxidopa, or the pharmaceutically acceptable salt thereof, for n days, wherein the total amount of droxidopa, or the pharmaceutically acceptable salt thereof, per package is about n*100 mg to about n*3000 mg or about n*100 mg to about n*1800 mg, preferably n is at least 3, 4, 5, 6, or 7.
E63. The solid composition of any one of embodiments 47 to 62, wherein the multi-particulate is in the form of a pellet, a granulate, or a mini-tablet.
E64. The solid composition of any one of embodiments 47 to 63, wherein the solid composition is packaged in a bottle or a sachet for suspension in a liquid vehicle.
E65. The solid composition of any one of embodiments 47 to 64, wherein
more than 20% of the droxidopa is released from the composition in 0.1 N HCl in 1 hour in a USP II apparatus (paddle) at 37° C. and 50 rpm; and
less than 10% of the droxidopa is released from the composition in water in 1 hour a USP II apparatus (paddle) at 37° C. and 50 rpm.
E66. The solid composition of any one of embodiments 47 to 65, wherein
more than 50% of the droxidopa is released from the composition in 0.1 N HCl in 6 hours in a USP II apparatus (paddle) at 37° C. and 50 rpm; and
less than 20% of the droxidopa is released from the composition in water in 6 hours a USP II apparatus (paddle) at 37° C. and 50 rpm.
E67. The solid composition of embodiment 65 or 66, wherein the solid composition is in the form of a tablet containing from about 100 mg to about 3000 mg or about 100 mg to about 1800 mg of droxidopa.
E68. The solid composition of any one of embodiments 47 to 67, wherein the extended-release multi-particulate further comprises an amount of a pH controlling agent sufficient to provide pH independent release of droxidopa from the multi-particulate.
E69. The solid composition of any one of embodiments 47 to 68, wherein the extended-release multi-particulate further comprises a pH controlling agent; and the amount of droxidopa released from the composition in 0. 1 N HCl in 1 hour in a USP II apparatus (paddle) at 37° C. and 50 rpm is equal within ±10% to the amount of droxidopa released from the composition in water in 1 hour in a USP II apparatus (paddle) at 37° C. and 50 rpm.
E70. The solid composition of embodiment 68 or 69, wherein the pH controlling agent is an organic acid selected from citric acid, tartaric acid, or a salt thereof.
E71. A pharmaceutical kit comprising:
the solid composition of any one of embodiments 47 to 70; and
a liquid vehicle.
E72. A pharmaceutical kit comprising: (a) a solid composition comprising a multi-particulate comprising: (i) a first multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and optionally a first release controlling agent; and (ii) a second multi-particulate comprising droxidopa, or a pharmaceutically acceptable salt thereof, and a second release controlling agent; and (b) a liquid vehicle.
E73. The kit of embodiment 71 or 72, in the form of a capped bottle wherein the solid composition is stored in a compartment within the cap of the bottle; and the liquid vehicle is stored in the bottle.
E74. A method of making an oral liquid dosage form, comprising mixing the solid composition of any one of embodiments 47 to 70 or the solid composition in the kit of any of embodiments 71 to 73 with a liquid vehicle or the liquid vehicle of the the kit of any of embodiments 71 to 73 to produce the liquid dosage form.
E75. The method of embodiment 74, wherein the liquid dosage form has a pH<7.0.
E76. The method of embodiment 74 or 75, wherein the liquid dosage form is a suspension or an emulsion.
E77. The method of any one of embodiments 74 to 76 or the kit of any one of embodiments 71 to 73, wherein the liquid vehicle is an aqueous vehicle.
E78. The method of any one of embodiment 74 to 76 or the kit of any one of embodiments 71 to 73, wherein the liquid vehicle is a nonaqueous vehicle.
E79. The method of any one of embodiments 74 to 76 or the kit of any one of embodiments 71 to 73, wherein the liquid vehicle comprises a polymer that forms an in situ gel in the gastrointestinal tract.
E80. The method of any one of embodiments 74 to 79, further comprising breaking a seal of the compartment within the cap of the bottle to release the composition into the liquid vehicle.
E81. A method of treating a subject, comprising
orally administering an effective amount of the liquid composition or suspension of any one of embodiments 1 to 46, the solid composition of any one of embodiments 47 to 70 or the solid composition in the kit of any one of embodiments 71 or 73, or the oral liquid dosage form made by the method of any one of embodiment 74 to 80 to a subject in need of treatment of hypotension, neurogenic orthostatic hypotension (nOH), intradialytic hypotension, a symptom of Parkinson's disease, orthostatic hypotension associated with Parkinson's disease, postural instability associated with Parkinson's disease, postural orthostatic tachycardia syndrome (POTS), Down's syndrome, a demyelinating disease, Alzheimer's disease, an attention deficit disorder, hypersomnia, pain associated with fibromyalgia, motor paralysis, motor aphasia, urinary incontinence, dementia, antidiuresis, postural tachycardia syndrome, tauopathy, fatigue, headaches, neurological deficits or neuronal death induced by brain ischemia, intracranial hypertension or cerebral edema, cancer, a bacterial infection, to induce or facilitate micturition, nasal congestion, acute pain, chronic pain, or any combination thereof.
E82. The method of embodiment 81, wherein the subject is in a supine position during administration.
E83. The method of embodiment 81 or 82, wherein the administering is once or twice daily.
E84. The method of any one of embodiments 81 to 83, wherein the total daily dose of droxidopa administered to the subject is 100 mg to 3000 mg or 100 mg to 1800 mg.
E85. The method of any one of embodiments 81 to 84, wherein the subject is in need of treatment of hypotension or a symptom of Parkinson's disease.
E86. The method of any one of embodiments 81 to 84, wherein the subject is in need of treatment of postural orthostatic tachycardia syndrome (POTS).
In general, the claimed invention may alternately comprise, consist of, or consist essentially of, any appropriate components herein disclosed. The claimed invention may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the claimed invention. The endpoints of all ranges directed to the same component or property are inclusive and independently combinable (e.g., ranges of “less than or equal to 25 wt %, or 5 wt % to 20 wt %,” is inclusive of the endpoints and all intermediate values of the ranges of “5 wt % to 25 wt %,” etc.). Disclosure of a narrower range or more specific group in addition to a broader range is not a disclaimer of the broader range or larger group. The suffix “(s)” as used herein is intended to include both the singular and the plural of the term that it modifies, thereby including one or more of that term (e.g., the film(s) includes one or more films). Reference throughout the specification to “one embodiment”, “another embodiment”, “an embodiment”, and so forth, means that a particular element (e.g., feature, structure, and/or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be understood that the described elements may be combined in any suitable manner in the various embodiments.
All cited patents, patent applications, and other references are incorporated herein by reference in their entirety. However, if a term in the present application contradicts or conflicts with a term in the incorporated reference, the term from the present application takes precedence over the conflicting term from the incorporated reference.
While particular embodiments have been described, alternatives, modifications, variations, improvements, and substantial equivalents that are or may be presently unforeseen may arise to applicants or others skilled in the art. Accordingly, the appended claims as filed and as they may be amended are intended to embrace all such alternatives, modifications variations, improvements, and substantial equivalents.
This application claims priority to U.S. Provisional Patent Application No. 62/438,056, filed on Dec. 22, 2016, which is incorporated by reference herein in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2017/068038 | 12/21/2017 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62438056 | Dec 2016 | US |
